Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Passage Bio (Nasdaq: PASG) announced the appointment of Dr. William Chou as its new CEO, granting him inducement stock options for 665,500 shares at an exercise price of $1.32 per share. These options will vest over four years, with 25% vesting after the first year and the remainder in monthly installments. The company focuses on developing gene therapies for central nervous system disorders, including GM1 gangliosidosis and Krabbe disease, and has established a collaboration with the University of Pennsylvania's Gene Therapy Program.
- Appointment of Dr. William Chou as CEO, indicating leadership stability.
- Inducement awards structured to align CEO incentives with shareholder interests.
- Focus on transformative gene therapies for CNS disorders, potentially expanding market opportunities.
- None.
PHILADELPHIA, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted inducement awards to its newly appointed chief executive officer, William Chou, M.D.
As part of Dr. Chou’s initial equity grant, Passage Bio granted options to purchase 665,500 shares of common stock to Dr. Chou as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of
The shares subject to the Inducement Options will vest over four years, with 25 percent of the shares vesting on the one-year anniversary of the applicable grant date, and the remainder vesting in 36 equal monthly installments thereafter, subject to each employee’s continued employment. The stock options have a 10-year term and are subject to the terms and conditions of the stock option agreement.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Our portfolio spans pediatric and adult CNS indications, and we are currently advancing three clinical programs in GM1 gangliosidosis, Krabbe disease and frontotemporal dementia with several additional programs in preclinical development. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. Through this collaboration, we have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.
For further information, please contact:
Passage Bio Investors:
Stuart Henderson
Passage Bio
267-866-0114
shenderson@passagebio.com
Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312-961-2502
MikeBeyer@sambrown.com
FAQ
What are the stock options granted to Dr. Chou at Passage Bio?
How will Dr. Chou's stock options vest?
What is the focus of Passage Bio?
What diseases is Passage Bio targeting with its therapies?
What collaboration has Passage Bio established?
